Summary
Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disease and in 93 age-matched normal control subjects. Sixty-nine patients and 54 control subjects were classified as slow acetylators (NS). No relation was found among acetylator polymorphism and age at onset or clinical stage of disease.
Amongst slow acetylators, the percentage of acetylated sulphamethazine in plasma was significantly lower in patients than in controls. Despite this finding, the results do not support any relationship between acetylator polymorphism and the risk of developing Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
References
Evans DAP, White TA (1964) Human acetylation polymorphism. J Lab Clin Med 63: 394–403
Evans DAP (1984) Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet 21: 243–253
Ladero JM, Kwok CK, Jara C, Fernández L, Silmi AM, Tapia D, Uson AC (1985) Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 17: 96–99
Weber WW (1987) The acetylator genes and drug response. Oxford University Press, New York
Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson's disease: 4-Hydroxylation of debrisoquine. Lancet 2: 1213–1216
Evans DAP (1969) An improved and simplified method of detecting the acetylator phenotype. J Med Genet 6: 405–407
Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17: 427–442
Lunde PKM, Frislid K, Hansteen V (1977) Disease and acetylation polymorphism. Clin Pharmacokinet 2: 182–197
Ladero J, Arrojo A, Sánchez de Paz F, Gilsanz V (1981) Efecto de la rifampicina sobre la acetilación hepática polimórfica. Gastroenterol Hepatol 4: 15–17
Sarma GR, Kailasam S, Nair NGK, Narayana ASL, Tripathy SP (1980) Effect of prednisone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother 18: 661–666
Wright JT, Goodman RP, Bethel AMM, Lambert CM (1984) Cimetidine and dapsone acetylation. Drug Metab Dispos 12: 782–783
Weber WW, King CM (1981) N-acetyltransferase and arylhydroxamic acid transferase. Methods Enzymol 77: 272–280
Schneck DW, Sprouse JS, Shiroff RA, Vary JE, DeWitt FO, Hayes AH (1979) Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway. Pharmacology 18: 34–41
Aubry JP, Biour M, Cheymol A, Jaillon P (1980) Modification de la détermination du phénotype d'acétylation au cours d'un traitement par la procaïnamide. Therapie 35: 653–654
Reilly DK, Rivera-Calimlim L, Van Dike D (1980) Catechol-0-methyltransferase activity: A determinant of levodopa response. Clin Pharmacol Ther 28: 278–286
Lower GM (1982) Concepts in causality: Chemically induced human urinary bladder cancer. Cancer 49: 1056–1066
Ladero JM, Arrojo A, Cocero E, Gómez M, Cano F, Franco C, Camarero E, Sánchez P (1983) Fenotipo acetilador hepático en la polineuropatia diabética. Rev Clin Esp 168: 399–402
Price J (1971) Demethylation, methylation and schizophrenia. A Pharmacogenetic study. MD Thesis, University of London (cited by Evans in [2])
Saiz-Ruiz J, Aguilera JC (1985) Personality traits and acetylator status. Biol Psychiatry 20: 1138–1140
Poirier J, Roy M, Campanella G, Cloutier T, Paris S (1987) Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs. Lancet 2: 386
Harmer D, Evans DAP, Eze LC, Jolly M, Whibley EJ (1986) The relationship between the acetylator and the sparteine hydroxylation polymorphisms. J Med Genet 23: 155–156
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ladero, J.M., Jimenez, F.J., Benitez, J. et al. Acetylator polymorphism in Parkinson's disease. Eur J Clin Pharmacol 37, 391–393 (1989). https://doi.org/10.1007/BF00558506
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558506